eF­FEC­TOR's lead lung can­cer pro­gram falls through, stock crash­es

eF­FEC­TOR Ther­a­peu­tics won’t be mov­ing its lead can­di­date for­ward in front­line non-small cell lung can­cer af­ter its ex­per­i­men­tal drug failed a Phase 2 study.

In the KICK­START tri­al, pa­tients with PD-L1 ≥50% re­ceived Mer­ck’s Keytru­da with ei­ther tomivosert­ib or place­bo as front­line treat­ment. Me­di­an pro­gres­sion-free sur­vival in the tomivosert­ib arm was 13 weeks com­pared to 11.7 weeks with place­bo, and the dif­fer­ence was not sta­tis­ti­cal­ly sig­nif­i­cant, eF­FEC­TOR re­port­ed on Thurs­day. Over­all sur­vival da­ta were im­ma­ture, but there was no trend fa­vor­ing the ex­per­i­men­tal arm.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER